Cover Image
市場調查報告書

再生醫療的全球市場預測 ∼2021年:各治療方法(細胞療法、人類組織工程、遺傳基因療法、免疫療法)、產品、用途

Regenerative Medicine Market by Therapy (Cell Therapy, Tissue Engineering, Immunotherapy, Gene Therapy), Product (Cell-Based, Acellular), Applications (Orthopedic & Musculoskeletal Disorders, Dermatology, Oncology, Cardiology) - Forecast to 2021

出版商 MarketsandMarkets 商品編碼 363089
出版日期 內容資訊 英文 140 Pages
訂單完成後即時交付
價格
Back to Top
再生醫療的全球市場預測 ∼2021年:各治療方法(細胞療法、人類組織工程、遺傳基因療法、免疫療法)、產品、用途 Regenerative Medicine Market by Therapy (Cell Therapy, Tissue Engineering, Immunotherapy, Gene Therapy), Product (Cell-Based, Acellular), Applications (Orthopedic & Musculoskeletal Disorders, Dermatology, Oncology, Cardiology) - Forecast to 2021
出版日期: 2017年02月10日 內容資訊: 英文 140 Pages
簡介

全球再生醫療的市場規模,預計從2016年到2021年以23.6%的年複合成長率(CAGR) 擴大,從2016年的130億4100萬美元,到2021年達到387億美元。該市場的高成長,是由於多樣的產品、技術及器官移植需求的劇增所帶來。

本報告提供全球再生醫療市場相關調查分析,市場概要,產業趨勢,各市場區隔的市場分析,競爭情形,主要企業等相關的系統性資訊。

第1章 簡介

第2章 調查手法

  • 市場規模的預測
  • 市場明細和資料的三角測量
  • 市場佔有率的預測

第3章 摘要整理

第4章 重要考察

  • 再生醫療市場:市場概要
  • 地區分析:再生醫療市場 各醫療法 2016年
  • 再生醫療市場:地區概要

第5章 市場概要

  • 簡介
  • 市場動態
  • 促進要素
    • 政府及民間對再生醫療發展的支援
    • 慢性疾病和遺傳基因疾病的增加
    • 醫療保健的支出的增加
    • 老年人口的急劇增加
    • 為了推動再生醫療的發展和商用化的企業聯盟的增加
  • 抑制因素
    • 在研究開發時ES細胞的使用面臨的道德問題點
    • 缺乏明確的法規指南
  • 機會
    • 器官移植的需求增加
    • 促進市場的強力產品平台

第6章 再生醫療的全球市場:各產品

  • 簡介
  • 細胞基礎產品
    • 自我細胞基礎
    • 同種異體細胞基礎
  • 無細胞產品

第7章 再生醫療的全球市場:各治療法

  • 簡介
  • 細胞療法
  • 遺傳基因療法
  • 人組織工程
  • 免疫療法

第8章 再生醫療的全球市場:各應用領域

  • 簡介
  • 整形外科、肌肉骨骼系統脊椎
  • 皮膚科
  • 心血管
  • 中樞神經系統
  • 癌症
  • 糖尿病
  • 其他

第9章 再生醫療市場:各地區

  • 簡介
  • 北美
    • 美國
    • 加拿大
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 其他歐洲各國(RoE)
  • 亞太地區
  • 其他各國(RoW)

第10章 競爭情形

  • 競爭概要
  • 市場排行榜
  • 競爭環境與趨勢
    • 企業收購
    • 產業聯盟
    • 法規核准
    • 新產品的開發
    • 其他

第11章 企業簡介

  • ACELITY L.P. INC. (KCI LICENSING)
  • NUVASIVE, INC.
  • VERICEL CORPORATION
  • OSIRIS THERAPEUTICS, INC.
  • INTEGRA LIFESCIENCES CORPORATION
  • STRYKER CORPORATION
  • MEDTRONIC PLC
  • COOK BIOTECH INCORPORATED
  • ORGANOGENESIS INC.
  • JAPAN TISSUE ENGINEERING CO., LTD. (SUBSIDIARY OF FUJIFILM HOLDINGS CORPORATION)

第12章 附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: BT 4419

Title: Regenerative Medicine Market by Therapy (Cell Therapy, Tissue Engineering, Immunotherapy, Gene Therapy), By Product (Cell-Based, Acellular), By Applications (Orthopedic & Musculoskeletal Disorders, Dermatology, Oncology, Cardiology)-Forecast To 2021.

"The global Regenerative medicine market is expected to reach USD 38.70 billion by 2021 from USD 13.41 billion in 2016 at a CAGR of 23.6% from 2016 to 2021."

The major factor driving the growth of regenerative medicine market, are government and private funding to support the development of regenerative medicine, rising prevalence of chronic diseases and genetic disorders, increase in global healthcare expenditure, and rapid growth in the aging population.

The global Regenerative medicine market is segmented based on type, therapy, application, and regions. The cell-based products segment is expected to register to have largest market share in the Regenerative medicine market, by type, during the forecast period. The high growth in this segment is attributed to the increasing awareness about stem cell therapy, growing funding for new stem cell lines, and development of advanced genomic methods.

On the basis of therapy, the cell therapy procedure is expected to account for the largest share of the market in 2016. Increasing funding from several agencies and private organizations for the research and development of cell therapies, growing inclination of the healthcare industry towards stem cell research, and increasing global awareness about the benefits of stem cell therapies will drive the growth of this market.

On the basis of applications, the segments are orthopedic & musculoskeletal disorders, dermatology, cardiology, diabetes, central nervous system diseases, and other applications. Oncology is the fastest growing application market. Increasing cancer incidence, rich product pipeline and increasing demand for cancer treatments fuelling the growth of the market.

Geographically, the Regenerative medicine market is dominated by North America, followed by Europe, Asia-Pacific, and the Rest of the World (RoW). Growth in the North American segment is primarily driven by rapidly increasing aging population and increase in chronic diseases are the major drivers for developed economies like the U.S.

The key players in the cell-based products segment are Organogenesis Inc. (U.S.), Osiris Therapeutics, Inc. (U.S.), Vericel Corporation (U.S.), Stryker Corporation (U.S.), and NuVasive, Inc. (U.S.). The key players in the acellular products segment are Medtronic (Ireland), Acelity (KCI Concepts) (U.S.), Integra LifeSciences (U.S.), Cook Biotech Inc. (U.S.), and C.R. Bard (U.S.).

Research Coverage:

The report analyses the Regenerative medicine market by type, therapy, application and regions. Apart from comprehensive geographic and product analysis and market sizing, the report also provides a competitive landscape that covers the growth strategies adopted by industry players over the last three years. In addition, the company profiles comprise the product portfolios, developments, and strategies adopted by the market players to maintain and increase their shares in the market. The above-mentioned market research data, current market size, and forecast of the future trends will help key market players and new entrants to make the necessary decisions regarding product offerings, geographic focus, change in strategic approach, and levels of output in order to remain successful in the Regenerative medicine market.

Reasons to Buy the Report:

This report will enable both established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn will help these firms garner greater market shares. Firms purchasing the report can use any one or a combination of the below-mentioned five strategies (market penetration, product development/innovation, market development, market diversification, and competitive assessment) for strengthening their market shares.

The report provides insights on the following pointers:

  • Market Penetration: Comprehensive information on the product portfolios of the top players in the Regenerative medicine market.
  • Product Development/Innovation: Detailed insights on the upcoming technologies, R&D activities, and new product launches in the Regenerative medicine market
  • Competitive Assessment: In-depth assessment of the market strategies, geographic and business segments, and product portfolios of the leading players in the Regenerative medicine market
  • Market Development: Comprehensive information about emerging markets. This report analyses the market for various Regenerative medicine market products across geographies
  • Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the Regenerative medicine market.

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. OBJECTIVES OF THE STUDY
  • 1.2. MARKET DEFINITION
  • 1.3. MARKET SCOPE
    • 1.3.1. MARKETS COVERED
    • 1.3.2. YEARS CONSIDERED FOR THE STUDY
  • 1.4. CURRENCY
  • 1.5. LIMITATIONS
  • 1.6. STAKEHOLDERS

2. RESEARCH METHODOLOGY

  • 2.1. MARKET SIZE ESTIMATION
  • 2.2. MARKET BREAKDOWN AND DATA TRIANGULATION
  • 2.3. MARKET SHARE ESTIMATION
    • 2.3.1. KEY DATA FROM SECONDARY SOURCES
    • 2.3.2. KEY DATA FROM PRIMARY SOURCES
    • 2.3.3. ASSUMPTIONS FOR THE STUDY

3. EXECUTIVE SUMMARY

4. PREMIUM INSIGHTS

  • 4.1. REGENERATIVE MEDICINE: MARKET OVERVIEW
  • 4.2. GEOGRAPHIC ANALYSIS: REGENERATIVE MEDICINE MARKET, BY THERAPY, 2016
  • 4.3. GEOGRAPHICAL SNAPSHOT OF THE REGENERATIVE MEDICINE MARKET

5. MARKET OVERVIEW

  • 5.1. INTRODUCTION
  • 5.2. MARKET DYNAMICS
  • 5.3. DRIVERS
    • 5.3.1. GOVERNMENT & PRIVATE FUNDING TO SUPPORT THE DEVELOPMENT OF REGENERATIVE MEDICINE
    • 5.3.2. RISING PREVALENCE OF CHRONIC DISEASES AND GENETIC DISORDERS
    • 5.3.3. INCREASE IN GLOBAL HEALTHCARE EXPENDITURE
    • 5.3.4. RAPID GROWTH IN THE AGING POPULATION
    • 5.3.5. INCREASE IN CORPORATE PARTNERSHIPS TO ACCELERATE DEVELOPMENT AND COMMERCIALIZATION OF REGENERATIVE MEDICINE
  • 5.4. RESTRAINTS
    • 5.4.1. ETHICAL CONCERNS WITH THE USE OF EMBRYONIC STEM CELL FOR R&D
    • 5.4.2. LACK OF CLEAR REGULATORY GUIDELINES
  • 5.5. OPPORTUNITIES
    • 5.5.1. RISING DEMAND FOR ORGAN TRANSPLANTATION
    • 5.5.2. STRONG PRODUCT PIPELINE

6. GLOBAL REGENERATIVE MEDICINE MARKET, BY PRODUCT

  • 6.1. INTRODUCTION
  • 6.2. CELL-BASED PRODUCTS
    • 6.2.1. ALLOGENEIC PRODUCTS
    • 6.2.2. AUTOLOGOUS PRODUCTS
  • 6.3. ACELLULAR PRODUCTS

7. GLOBAL REGENERATIVE MEDICINE MARKET, BY THERAPY

  • 7.1. INTRODUCTION
  • 7.2. CELL THERAPY
  • 7.3. TISSUE ENGINEERING
  • 7.4. IMMUNOTHERAPY
  • 7.5. GENE THERAPY

8. REGENERATIVE MEDICINE MARKET, BY APPLICATION

  • 8.1. INTRODUCTION
  • 8.2. ORTHOPEDIC & MUSCULOSKELETAL DISORDERS
  • 8.3. DERMATOLOGY
  • 8.4. CARDIOLOGY
  • 8.5. CENTRAL NERVOUS SYSTEM DISEASES
  • 8.6. ONCOLOGY
  • 8.7. DIABETES
  • 8.8. OTHER APPLICATIONS

9. GLOBAL REGENERATIVE MEDICINE MARKET, BY REGION

  • 9.1. INTRODUCTION
  • 9.2. NORTH AMERICA
    • 9.2.1. U.S.
    • 9.2.2. CANADA
  • 9.3. EUROPE
    • 9.3.1. GERMANY
    • 9.3.2. U.K.
    • 9.3.3. FRANCE
    • 9.3.4. ITALY
    • 9.3.5. SPAIN
    • 9.3.6. REST OF EUROPE (ROE)
  • 9.4. ASIA-PACIFIC
  • 9.5. REST OF THE WORLD (ROW)

10. COMPETITIVE LANDSCAPE

  • 10.1. OVERVIEW
  • 10.2. MARKET RANKING
  • 10.3. COMPETITIVE SITUATION AND TRENDS
    • 10.3.1. ACQUISITIONS
    • 10.3.2. PARTNERSHIPS
    • 10.3.3. REGULATORY APPROVALS
    • 10.3.4. NEW PRODUCT DEVELOPMENTS
    • 10.3.5. OTHERS

11. COMPANY PROFILES (Overview, Financial*, Products & Services, Strategy, and Developments)

  • 11.1. ACELITY L.P. INC. (KCI LICENSING)
  • 11.2. NUVASIVE, INC.
  • 11.3. VERICEL CORPORATION
  • 11.4. OSIRIS THERAPEUTICS, INC.
  • 11.5. INTEGRA LIFESCIENCES CORPORATION
  • 11.6. STRYKER CORPORATION
  • 11.7. MEDTRONIC PLC
  • 11.8. COOK BIOTECH INCORPORATED
  • 11.9. ORGANOGENESIS INC.
  • 11.10. JAPAN TISSUE ENGINEERING CO., LTD. (SUBSIDIARY OF FUJIFILM HOLDINGS CORPORATION)

*Details might not be captured in case of unlisted companies.

12. APPENDIX

  • 12.1. INSIGHTS FROM INDUSTRY EXPERTS
  • 12.2. DISCUSSION GUIDE
  • 12.3. KNOWLEDGE STORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 12.4. INTRODUCING RT: REAL-TIME MARKET INTELLIGENCE
  • 12.5. AVAILABLE CUSTOMIZATIONS
  • 12.6. RELATED REPORTS
  • 12.7. AUTHOR DETAILS

LIST OF TABLES

  • TABLE 1: KEY CORPORATE PARTNERSHIPS, 2016
  • TABLE 2: GENE THERAPY PRODUCTS IN CLINICAL TRIALS, 2016
  • TABLE 3: CELL AND GENE THERAPY CLINICAL PRODUCT PIPELINE, 2016
  • TABLE 4: GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY PRODUCT, 2014-2021 (USD BILLION)
  • TABLE 5: CELL-BASED PRODUCTS MARKET SIZE, BY REGION, 2014-2021 (USD BILLION)
  • TABLE 6: CELL-BASED PRODUCTS MARKET SIZE, BY TYPE, 2014-2021 (USD BILLION)
  • TABLE 7: ALLOGENEIC PRODUCTS MARKET SIZE, BY REGION, 2014-2021 (USD BILLION)
  • TABLE 8: AUTOLOGOUS PRODUCTS MARKET SIZE, BY REGION, 2014-2021 (USD BILLION)
  • TABLE 9: ACELLULAR PRODUCTS MARKET SIZE, BY REGION, 2014-2021 (USD BILLION)
  • TABLE 10: GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY THERAPY, 2014-2021 (USD BILLION)
  • TABLE 11: STEM CELL THERAPIES IN PHASE III DEVELOPMENT, 2016
  • TABLE 12: CELL THERAPY MARKET SIZE, BY REGION, 2014-2021 (USD BILLION)
  • TABLE 13: TISSUE ENGINEERING MARKET SIZE, BY REGION, 2014-2021 (USD BILLION)
  • TABLE 14: IMMUNOTHERAPY MARKET SIZE, BY REGION, 2014-2021 (USD BILLION)
  • TABLE 15: GENE THERAPIES IN CLINICAL TRIALS, 2016
  • TABLE 16: GENE THERAPY MARKET SIZE, BY REGION, 2014-2021 (USD BILLION)
  • TABLE 17: NUMBER OF CLINICAL TRIALS FOR REGENERATIVE MEDICINE, BY THERAPEUTIC CATEGORY (2016)
  • TABLE 18: NUMBER OF CLINICAL TRIALS FOR REGENERATIVE MEDICINE, BY PHASE (2016)
  • TABLE 19: REGENERATIVE MEDICINE MARKET SIZE, BY APPLICATION, 2014-2021 (USD BILLION)
  • TABLE 20: ORTHOPEDIC & MUSCULOSKELETAL DISORDERS MARKET SIZE, BY REGION, 2014-2021 (USD BILLION)
  • TABLE 21: DERMATOLOGY MARKET SIZE, BY REGION, 2014-2021 (USD BILLION)
  • TABLE 22: CARDIOLOGY MARKET SIZE, BY REGION, 2014-2021 (USD BILLION)
  • TABLE 23: CENTRAL NERVOUS SYSTEM DISEASES MARKET SIZE, BY REGION, 2014-2021 (USD BILLION)
  • TABLE 24: CANCER PATIENTS (GLOBAL), BY CANCER TYPE, 2015-2035
  • TABLE 25: ONCOLOGY MARKET SIZE, BY REGION, 2014-2021 (USD BILLION)
  • TABLE 26: DIABETES MARKET SIZE, BY REGION, 2014-2021 (USD BILLION)
  • TABLE 27: OTHER APPLICATIONS MARKET SIZE, BY REGION, 2014-2021 (USD BILLION)
  • TABLE 28: GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY REGION, 2014-2021 (USD BILLION)
  • TABLE 29: NORTH AMERICA: REGENERATIVE MEDICINE MARKET SIZE, BY COUNTRY, 2014-2021 (USD BILLION)
  • TABLE 30: NORTH AMERICA: REGENERATIVE MEDICINE MARKET SIZE, BY PRODUCT, 2014-2021 (USD BILLION)
  • TABLE 31: NORTH AMERICA: CELL-BASED PRODUCTS MARKET SIZE, BY TYPE, 2014-2021 (USD BILLION)
  • TABLE 32: NORTH AMERICA: REGENERATIVE MEDICINE MARKET SIZE, BY APPLICATION, 2014-2021 (USD BILLION)
  • TABLE 33: NORTH AMERICA: REGENERATIVE MEDICINE MARKET SIZE, BY THERAPY, 2014-2021 (USD BILLION)
  • TABLE 34: U.S.: REGENERATIVE MEDICINE MARKET SIZE, BY PRODUCT, 2014-2021 (USD BILLION)
  • TABLE 35: U.S.: CELL-BASED PRODUCTS MARKET SIZE, BY TYPE, 2014-2021 (USD BILLION)
  • TABLE 36: U.S.: REGENERATIVE MEDICINE MARKET SIZE, BY APPLICATION, 2014-2021 (USD BILLION)
  • TABLE 37: U.S.: REGENERATIVE MEDICINE MARKET SIZE, BY THERAPY, 2014-2021 (USD BILLION)
  • TABLE 38: CANADA: REGENERATIVE MEDICINE MARKET SIZE, BY PRODUCT, 2014-2021 (USD BILLION)
  • TABLE 39: CANADA: CELL-BASED PRODUCTS MARKET SIZE, BY TYPE, 2014-2021 (USD BILLION)
  • TABLE 40: CANADA: REGENERATIVE MEDICINE MARKET SIZE, BY APPLICATION, 2014-2021 (USD BILLION)
  • TABLE 41: CANADA: REGENERATIVE MEDICINE MARKET SIZE, BY THERAPY, 2014-2021 (USD BILLION)
  • TABLE 42: EUROPE: REGENERATIVE MEDICINE MARKET SIZE, BY COUNTRY, 2014-2021 (USD BILLION)
  • TABLE 43: EUROPE: REGENERATIVE MEDICINE MARKET SIZE, BY PRODUCT, 2014-2021 (USD BILLION)
  • TABLE 44: EUROPE: CELL-BASED PRODUCTS MARKET SIZE, BY TYPE, 2014-2021 (USD BILLION)
  • TABLE 45: EUROPE: REGENERATIVE MEDICINE MARKET SIZE, BY APPLICATION, 2014-2021 (USD BILLION)
  • TABLE 46: EUROPE: REGENERATIVE MEDICINE MARKET SIZE, BY THERAPY, 2014-2021 (USD BILLION)
  • TABLE 47: GERMANY: REGENERATIVE MEDICINE MARKET SIZE, BY PRODUCT, 2014-2021 (USD BILLION)
  • TABLE 48: GERMANY: CELL-BASED PRODUCTS MARKET SIZE, BY TYPE, 2014-2021 (USD BILLION)
  • TABLE 49: GERMANY: REGENERATIVE MEDICINE MARKET SIZE, BY APPLICATION, 2014-2021 (USD BILLION)
  • TABLE 50: GERMANY: REGENERATIVE MEDICINE MARKET SIZE, BY THERAPY, 2014-2021 (USD BILLION)
  • TABLE 51: U.K.: REGENERATIVE MEDICINE MARKET SIZE, BY PRODUCT, 2014-2021 (USD BILLION)
  • TABLE 52: U.K.: CELL-BASED PRODUCTS MARKET SIZE, BY TYPE, 2014-2021 (USD BILLION)
  • TABLE 53: U.K.: REGENERATIVE MEDICINE MARKET SIZE, BY APPLICATION, 2014-2021 (USD BILLION)
  • TABLE 54: U.K.: REGENERATIVE MEDICINE MARKET SIZE, BY THERAPY, 2014-2021 (USD BILLION)
  • TABLE 55: FRANCE: REGENERATIVE MEDICINE MARKET SIZE, BY PRODUCT, 2014-2021 (USD BILLION)
  • TABLE 56: FRANCE: CELL-BASED PRODUCTS MARKET SIZE, BY TYPE, 2014-2021 (USD BILLION)
  • TABLE 57: FRANCE: REGENERATIVE MEDICINE MARKET SIZE, BY APPLICATION, 2014-2021 (USD BILLION)
  • TABLE 58: FRANCE: REGENERATIVE MEDICINE MARKET SIZE, BY THERAPY, 2014-2021 (USD BILLION)
  • TABLE 59: ITALY: REGENERATIVE MEDICINE MARKET SIZE, BY PRODUCT, 2014-2021 (USD BILLION)
  • TABLE 60: ITALY: CELL-BASED PRODUCTS MARKET SIZE, BY TYPE, 2014-2021 (USD BILLION)
  • TABLE 61: ITALY: REGENERATIVE MEDICINE MARKET SIZE, BY APPLICATION, 2014-2021 (USD BILLION)
  • TABLE 62: ITALY: REGENERATIVE MEDICINE MARKET SIZE, BY THERAPY, 2014-2021 (USD BILLION)
  • TABLE 63: SPAIN: REGENERATIVE MEDICINE MARKET SIZE, BY PRODUCT, 2014-2021 (USD BILLION)
  • TABLE 64: SPAIN: CELL-BASED PRODUCTS MARKET SIZE, BY TYPE, 2014-2021 (USD BILLION)
  • TABLE 65: SPAIN: REGENERATIVE MEDICINE MARKET SIZE, BY APPLICATION, 2014-2021 (USD BILLION)
  • TABLE 66: SPAIN: REGENERATIVE MEDICINE MARKET SIZE, BY THERAPY, 2014-2021 (USD BILLION)
  • TABLE 67: ROE: REGENERATIVE MEDICINE MARKET SIZE, BY PRODUCT, 2014-2021 (USD BILLION)
  • TABLE 68: ROE: CELL-BASED PRODUCTS MARKET SIZE, BY TYPE, 2014-2021 (USD BILLION)
  • TABLE 69: ROE: REGENERATIVE MEDICINE MARKET SIZE, BY APPLICATION, 2014-2021 (USD BILLION)
  • TABLE 70: ROE: REGENERATIVE MEDICINE MARKET SIZE, BY THERAPY, 2014-2021 (USD BILLION)
  • TABLE 71: ASIA-PACIFIC: REGENERATIVE MEDICINE MARKET SIZE, BY PRODUCT, 2014-2021 (USD BILLION)
  • TABLE 72: ASIA: CELL-BASED PRODUCTS MARKET SIZE, BY TYPE, 2014-2021 (USD BILLION)
  • TABLE 73: ASIA-PACIFIC: REGENERATIVE MEDICINE MARKET SIZE, BY APPLICATION, 2014-2021 (USD BILLION)
  • TABLE 74: ASIA-PACIFIC: REGENERATIVE MEDICINE MARKET SIZE, BY THERAPY, 2013-2021 (USD BILLION)
  • TABLE 75: ROW: REGENERATIVE MEDICINE MARKET SIZE, BY PRODUCT, 2014-2021 (USD BILLION)
  • TABLE 76: ROW: CELL-BASED PRODUCTS MARKET SIZE, BY TYPE, 2014-2021 (USD BILLION)
  • TABLE 77: ROW: REGENERATIVE MEDICINE MARKET SIZE, BY APPLICATION, 2014-2021 (USD BILLION)
  • TABLE 78: ROW: REGENERATIVE MEDICINE MARKET SIZE, BY THERAPY, 2014-2021 (USD BILLION)
  • TABLE 79: RANKING OF MAJOR PLAYERS IN THE GLOBAL CELL-BASED REGENERATIVE MEDICINE MARKET (2015)
  • TABLE 80: RANKING OF MAJOR PLAYERS IN THE GLOBAL ACELLULAR REGENERATIVE MEDICINE MARKET (2015)
  • TABLE 81: KEY PRODUCTS IN THE CELL-BASED REGENERATIVE MEDICINE MARKET (2015)
  • TABLE 82: KEY PRODUCTS IN THE ACELLULAR REGENERATIVE MEDICINE MARKET (2015)
  • TABLE 83: ACQUISITIONS, 2014-2017
  • TABLE 84: PARTNERSHIPS, 2014-2016
  • TABLE 85: REGULATORY APPROVALS, 2014-2016
  • TABLE 86: NEW PRODUCT DEVELOPMENTS, 2013-2016
  • TABLE 87: OTHERS, 2014-2016

LIST OF FIGURES

  • FIGURE 1: RESEARCH DESIGN
  • FIGURE 2: MARKET SIZE ESTIMATION METHODOLOGY: BOTTOM-UP APPROACH
  • FIGURE 3: MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH
  • FIGURE 4: BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
  • FIGURE 5: DATA TRIANGULATION METHODOLOGY
  • FIGURE 6: CELL-BASED PRODUCTS TO LEAD THE MARKET DURING THE FORECAST PERIOD
  • FIGURE 7: CELL THERAPY TO DOMINATE THE REGENERATIVE MEDICINE MARKET BY 2021
  • FIGURE 8: GLOBAL REGENERATIVE MEDICINE MARKET, BY APPLICATION, 2016 VS. 2021
  • FIGURE 9: NORTH AMERICA TO LEAD THE REGENERATIVE MEDICINE MARKET DURING THE FORECAST PERIOD
  • FIGURE 10: GLOBAL REGENERATIVE MEDICINE MARKET TO REGISTER HIGH, DOUBLE-DIGIT GROWTH FROM 2016 TO 2021
  • FIGURE 11: CELL THERAPY SEGMENT TO DOMINATE THE REGENERATIVE MEDICINE MARKET IN 2016
  • FIGURE 12: ASIA-PACIFIC TO BE THE FASTEST-GROWING REGION IN THE FORECAST PERIOD
  • FIGURE 13: GLOBAL REGENERATIVE MEDICINE MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
  • FIGURE 14: GLOBAL REGENERATIVE MEDICINE MARKET SEGMENTATION, BY PRODUCT
  • FIGURE 15: CELL-BASED PRODUCTS TO COMMAND THE LARGEST SHARE OF THE GLOBAL REGENERATIVE MEDICINE MARKET IN 2016
  • FIGURE 16: CELL-BASED PRODUCTS MARKET SEGMENTATION, BY TYPE
  • FIGURE 17: CELL THERAPY TO DOMINATE THE REGENERATIVE MEDICINE MARKET DURING THE FORECAST PERIOD
  • FIGURE 18: ORTHOPEDIC & MUSCULOSKELETAL DISORDERS SEGMENT TO DOMINATE THE REGENERATIVE MEDICINE APPLICATIONS MARKET IN 2016
  • FIGURE 19: NUMBER OF DIABETES CASES, 2015 VS. 2040 (MILLION)
  • FIGURE 20: NORTH AMERICA: REGENERATIVE MEDICINE MARKET SNAPSHOT
  • FIGURE 21: NORTH AMERICA: REGENERATIVE MEDICINE MARKET SIZE, BY PRODUCT, 2014-2021 (USD BILLION)
  • FIGURE 22: U.S.: REGENERATIVE MEDICINE MARKET SIZE, BY PRODUCT, 2014-2021 (USD BILLION)
  • FIGURE 23: EUROPE: REGENERATIVE MEDICINE MARKET SNAPSHOT
  • FIGURE 24: EUROPE: REGENERATIVE MEDICINE MARKET SIZE, BY THERAPY, 2014-2021 (USD BILLION)
  • FIGURE 25: GERMANY: REGENERATIVE MEDICINE MARKET SIZE, BY PRODUCT, 2014-2021 (USD BILLION)
  • FIGURE 26: ASIA-PACIFIC: REGENERATIVE MEDICINE MARKET SNAPSHOT
  • FIGURE 27: ASIA-PACIFIC.: REGENERATIVE MEDICINE MARKET SIZE, BY PRODUCT, 2014-2021 (USD BILLION)
  • FIGURE 28: REST OF THE WORLD: REGENERATIVE MEDICINE MARKET SNAPSHOT
  • FIGURE 29: ROW: REGENERATIVE MEDICINE MARKET SIZE, BY THERAPY, 2014-2021 (USD BILLION)
  • FIGURE 30: LEADING MARKET PLAYERS ADOPTED BOTH ORGANIC AND INORGANIC GROWTH STRATEGIES OVER THE LAST FOUR YEARS (2013-2017)
  • FIGURE 31: BATTLE FOR MARKET SHARE: NEW PRODUCT LAUNCHES & PRODUCT ENHANCEMENTS ARE THE KEY STRATEGIES
  • FIGURE 32: ACELITY (KCI LICENSING): COMPANY SNAPSHOT (2015)
  • FIGURE 33: NUVASIVE, INC.: COMPANY SNAPSHOT (2015)
  • FIGURE 34: VERICEL CORPORATION: COMPANY SNAPSHOT (2015)
  • FIGURE 35: OSIRIS THERAPEUTICS, INC.: COMPANY SNAPSHOT (2014)
  • FIGURE 36: INTEGRA LIFESCIENCES CORPORATION: COMPANY SNAPSHOT (2015)
  • FIGURE 37: MEDTRONIC PLC: COMPANY SNAPSHOT (2016)
  • FIGURE 38: JAPAN TISSUE ENGINEERING CO., LTD: COMPANY SNAPSHOT (2015)
Back to Top